ClinicalTrials.gg
Active, not recruitingNCT05630755Updated Nov 18, 2025Results posted

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

A Phase 3 interventional study of DOR/ISL and BIC/FTC/TAF in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) at Week 48; and to evaluate the safety and tolerability of a switch to DOR/ISL compared with continued BIC/FTC/TAF, through Week 48. The primary hypotheses are that (1) DOR/ISL is non-inferior to continued BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority; and (2) DOR/ISL is superior to BIC/FTC/TAF, as assessed by the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Is -1 positive with plasma HIV-1 RNA \<50 copies/mL
  • Has been receiving BIC/FTC/TAF therapy with documented viral suppression (HIV-1 RNA \<50 copies/mL) for ≥3 consecutive months prior to providing documented and has no history of prior virologic treatment failure on any past or current regimen
  • Female is not a participant of (POCBP); or if a participant of childbearing potential, not pregnant or breastfeeding, and is willing to use an acceptable method or abstain from heterosexual intercourse for study duration

Exclusion criteria

Exclusion Criteria:

  • Has -2 infection
  • Has a diagnosis of an active acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within 30 days prior to screening
  • Has active virus (HBV) infection
  • Has chronic virus (HCV) infection with laboratory values consistent with cirrhosis
  • Has a history of ≤5 years prior to providing documented except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
  • Is taking or is anticipated to require systemic therapy, immune modulators, or strong and moderate cytochrome P450 3A () inducers
  • Has a documented or known virologic resistance to DOR
  • Has taken long-acting HIV therapy at any time (e.g., cabotegravir, lenacapavir)
  • Is currently participating in or has participated in a clinical study and received (or is receiving) an compound or device from 45 days prior to Day 1 through the study treatment period except those currently enrolled in the comparator arm of an ongoing DOR/ISL study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    DOR/ISL and Placebo to BIC/FTC/TAF

    Participants will receive DOR/ISL 100 mg/0.25 mg and Placebo to BIC/FTC/TAF once daily (QD) orally from day 1 to week 144. After week 144, eligible participants may continue on DOR/ISL and continue study treatment until week 240 or to when DOR/ISL becomes commercially accessible (whichever comes first).

    Drug: DOR/ISL · Drug: Placebo to BIC/FTC/TAF

  • Active comparator
    BIC/FTC/TAF and Placebo to DOR/ISL

    Participants will receive BIC/FTC/TAF 50 mg/200 mg/25 mg and Placebo to DOR/ISL once daily (QD) orally from day 1 to week 144. After week 144, eligible participants may switch to DOR/ISL and continue study treatment until week 240 or to when DOR/ISL becomes commercially accessible (whichever comes first).

    Drug: BIC/FTC/TAF · Drug: Placebo to DOR/ISL

Interventions

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    DOR/ISL 100 mg/0.25 mg oral tablets once daily

    Also known as: MK-8591A, Doravirine/Islatravir

  • DrugBIC/FTC/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily

    Also known as: Bictegravir/Emtricitabine/Tenofovir Alafenamide

  • DrugPlacebo to BIC/FTC/TAF

    0 mg oral tablets once daily

  • DrugPlacebo to DOR/ISL

    0 mg oral tablets once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48

    HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 48

  2. Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE is reported.

    Time frame: Up to Week 48

  3. Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.

    Time frame: Up to Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48

    HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 48

  2. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

    HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 48

  3. Change From Baseline in Cluster of Differentiation 4-positive (CD4+) T-cell Count at Week 48

    Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The change from baseline to Week 48 and corresponding 2-sided 95% confidence intervals were calculated based on cLDA models adjusted by treatment group, time, and the interaction of time-by-treatment group.

    Time frame: Baseline at Day 1 and Week 48

  4. Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48

    Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA ≥200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA ≥200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Per protocol, participants with HIV-1 RNA ≥400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.

    Time frame: Up to Week 48

  5. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96

    Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 will be reported.

    Time frame: Week 96

  6. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96

    Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 will be reported.

    Time frame: Week 96

  7. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

    Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 will be reported.

    Time frame: Week 96

  8. Change From Baseline in CD4+ T-cell Count at Week 96

    Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96 will be reported.

    Time frame: Baseline at Day 1 and Week 96

  9. Number of Participants With Viral Drug Resistance Mutations at Week 96

    Number of participants with evidence of viral drug resistance-associated substitutions at Week 96 will be reported.

    Time frame: Week 96

  10. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144

    Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 will be reported.

    Time frame: Week 144

  11. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144

    Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 will be reported.

    Time frame: Week 144

  12. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

    Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 will be reported.

    Time frame: Week 144

  13. Change From Baseline in CD4+ T-cell Count at Week 144

    Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144 will be reported.

    Time frame: Baseline at Day 1 and Week 144

  14. Number of Participants With Viral Drug Resistance Mutations at Week 144

    Number of participants with evidence of viral drug resistance-associated substitutions at Week 144 will be reported.

    Time frame: Week 144

  15. Percentage of Participants Who Experience AEs Through Week 144

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 144

  16. Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 144

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 144

07

Results

Posted Nov 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Started343171
Treated342171
Completed106
Not completed333165
Withdrew: Lost to follow-up70
Withdrew: Randomized by mistake without study treatment10
Withdrew: Withdrawal by subject93
Withdrew: Participant moved away from trial site01
Withdrew: Status not recorded316161

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48

HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 48
Percentage of ParticipantsDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥50 Copies/mL at Week 481.50.6
Statistical analysis
  • DOR/ISL and Placebo to BIC/FTC/TAF vs BIC/FTC/TAF and Placebo to DOR/ISL · Miettinen and Nurminen method · p = 0.003 · Risk difference (rd): 0.88 · 95% CI -1.86 to 2.90Unstratified Miettinen and Nurminen method was used
  • DOR/ISL and Placebo to BIC/FTC/TAF vs BIC/FTC/TAF and Placebo to DOR/ISL · Miettinen and Nurminen method · p = 0.192 · Risk difference (rd): 0.88 · 95% CI -1.86 to 2.90Unstratified Miettinen and Nurminen method was used
PrimaryPercentage of Participants Who Experience Adverse Events (AEs) Through Week 48

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE is reported.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experience Adverse Events (AEs) Through Week 48
Percentage of ParticipantsDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Percentage of Participants Who Experience Adverse Events (AEs) Through Week 4874.671.3
PrimaryPercentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 48
Percentage of ParticipantsDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Percentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 482.91.8
SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48

HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
Percentage of ParticipantsDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 4891.894.2
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

HIV-1 RNA levels in blood samples taken at each visit were measured with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
Percentage of ParticipantsDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 4891.594.2
SecondaryChange From Baseline in Cluster of Differentiation 4-positive (CD4+) T-cell Count at Week 48

Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The change from baseline to Week 48 and corresponding 2-sided 95% confidence intervals were calculated based on cLDA models adjusted by treatment group, time, and the interaction of time-by-treatment group.

Time frame:
Baseline at Day 1 and Week 48
Reported as:
Mean · Cells/mm^3
Change From Baseline in Cluster of Differentiation 4-positive (CD4+) T-cell Count at Week 48
Cells/mm^3DOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Change From Baseline in Cluster of Differentiation 4-positive (CD4+) T-cell Count at Week 4830.40 (10.98 to 49.83)28.19 (-4.46 to 60.83)
SecondaryPercentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48

Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA ≥200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA ≥200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Per protocol, participants with HIV-1 RNA ≥400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48
Percentage of ParticipantsDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 480—
SecondaryPercentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96

Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 will be reported.

Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96

Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 will be reported.

Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 will be reported.

Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryChange From Baseline in CD4+ T-cell Count at Week 96

Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96 will be reported.

Time frame:
Baseline at Day 1 and Week 96

Results for this outcome have not been posted.

SecondaryNumber of Participants With Viral Drug Resistance Mutations at Week 96

Number of participants with evidence of viral drug resistance-associated substitutions at Week 96 will be reported.

Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144

Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 will be reported.

Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144

Percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 will be reported.

Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

Percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 will be reported.

Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryChange From Baseline in CD4+ T-cell Count at Week 144

Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144 will be reported.

Time frame:
Baseline at Day 1 and Week 144

Results for this outcome have not been posted.

SecondaryNumber of Participants With Viral Drug Resistance Mutations at Week 144

Number of participants with evidence of viral drug resistance-associated substitutions at Week 144 will be reported.

Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Experience AEs Through Week 144

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Discontinue Study Intervention Due to AEs Through Week 144

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Week 144

Results for this outcome have not been posted.

Adverse events

Collected over Up to 84 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DOR/ISL and Placebo to BIC/FTC/TAF0/343 (0%)15/342 (4.4%)94/342 (27.5%)
BIC/FTC/TAF and Placebo to DOR/ISL0/171 (0%)11/171 (6.4%)52/171 (30.4%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
CellulitisInfections and infestations0/3423/171
AnaemiaBlood and lymphatic system disorders0/3421/171
Pancreatitis acuteGastrointestinal disorders2/3420/171
Anal abscessInfections and infestations0/3421/171
Herpes simplexInfections and infestations0/3421/171
OrchitisInfections and infestations0/3421/171
PneumoniaInfections and infestations1/3421/171
HaemarthrosisMusculoskeletal and connective tissue disorders0/3421/171
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3421/171
Generalised anxiety disorderPsychiatric disorders0/3421/171
Most frequent other events
Most frequent other events
EventDOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISL
NasopharyngitisInfections and infestations21/34213/171
FatigueGeneral disorders13/34212/171
ArthralgiaMusculoskeletal and connective tissue disorders22/3428/171
COVID-19Infections and infestations21/3429/171
DiarrhoeaGastrointestinal disorders20/3426/171
InfluenzaInfections and infestations9/3429/171
DizzinessNervous system disorders11/3429/171

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISLTotal
Mean47.6 ± 12.947.6 ± 13.147.6 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)DOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISLTotal
Female7436110
Male269135404
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISLTotal
Hispanic or Latino7344117
Not Hispanic or Latino262125387
Unknown or Not Reported8210
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DOR/ISL and Placebo to BIC/FTC/TAFBIC/FTC/TAF and Placebo to DOR/ISLTotal
American Indian or Alaska Native011
Asian201030
Native Hawaiian or Other Pacific Islander000
Black or African American11247159
White206106312
More than one race369
Unknown or Not Reported213
08

Study locations

49 sites
09

References and documents

Publications

  • Diamond TL, Grandhi A, Fuszard M, Xu Y, Nwoke U, Zhang Y, Klopfer SO, Eves K, Benner J, Li M, Greaves W, Lahoulou R, Kim J, Fox MC, Asante-Appiah E. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA. J Infect Dis. 2026 May 29:jiag257. doi: 10.1093/infdis/jiag257. Online ahead of print. PubMed 42213454 ↗
  • Colson AE, Mills AM, Ramgopal MN, Bettacchi C, Osiyemi OO, Hinestrosa F, Crofoot G, Katner HP, Gatanaga H, Johnson M, Diamond TL, Barninger E, Eves K, Su FH, Xu Y, Klopfer SO, Stamm LM, Fox MC, Lahoulou R. Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Lancet. 2026 Feb 7;407(10528):611-621. doi: 10.1016/S0140-6736(25)01948-8. PubMed 41654375 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Oct 2024, 20 months.

Results were first posted in Nov 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Nov 30, 2022
StartActual
Feb 17, 2023
Primary completionActual
Oct 25, 2024
CompletionEst.
Aug 4, 2028
Results first posted
Nov 18, 2025
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05630755
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Feb 17, 2023
Primary completion
Oct 25, 2024
Completion
Aug 4, 2028 (estimated)
Results posted
Nov 18, 2025
Last update
Nov 18, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion